Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00993239 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
A Phase 1 study, sponsored by TetraLogic Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT00993239: Completed Phase 1 study, sponsored by TetraLogic Pharmaceuticals.
NCT00993239 is a Phase 1 study that has completed, run by TetraLogic Pharmaceuticals. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00993239, a Phase 1 study, has completed, sponsored by TetraLogic Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
A Phase 1 open-label, non-randomized dose escalation study to determine the maximum tolerated dose (MTD) and characterize the safety and tolerability of Birinapant (TL32711).
Interventions
- DRUG Birinapant (TL32711)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2009-11 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00993239
The ClinicalTrials.gov registry entry for NCT00993239 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TetraLogic Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Birinapant (TL32711) is the first listed.
NCT00993239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00993239 about?
NCT00993239 is a clinical study titled "Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma". A Phase 1 open-label, non-randomized dose escalation study to determine the maximum tolerated dose (MTD) and characterize the safety and tolerability of Birinapant (TL32711).
What is the current status of trial NCT00993239?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2009-11. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00993239?
The interventions under investigation include: Birinapant (TL32711) (DRUG).
Who is sponsoring clinical trial NCT00993239?
This trial is sponsored by TetraLogic Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.